Inozyme Pharma, Inc.
INZYDelisted Jul 1, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001693011
Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in Inozyme Pharma, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +16 vs. Q3 2024
- Shares held
- 52.4M
- −2.19M (−4.0%) vs. Q3 2024
- Total value
- $145.1M
- −$140.4M (−49.2%) vs. Q3 2024
- New holders
- 35
- 34 more added
- Sold out
- 19
- 17 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INZY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 87 | $202.3M |
| Q1 2025 | 97 | $42.5M |
| Q4 2024 | 105 | $145.1M |
| Q3 2024 | 89 | $285.5M |
| Q2 2024 | 90 | $240.1M |
| Q1 2024 | 89 | $382.0M |
| Q4 2023 | 80 | $213.3M |
| Q3 2023 | 77 | $204.6M |
| Q2 2023 | 74 | $190.3M |
| Q1 2023 | 50 | $183.4M |
| Q4 2022 | 37 | $30.4M |
| Q3 2022 | 39 | $82.7M |
| Q2 2022 | 47 | $149.4M |
| Q1 2022 | 50 | $71.2M |
| Q4 2021 | 51 | $118.2M |
| Q3 2021 | 52 | $202.7M |
| Q2 2021 | 50 | $337.1M |
| Q1 2021 | 55 | $379.4M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Inozyme Pharma, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rock Springs Capital Management LP | 3,861,983 | $10.7M | 0.41% | +59,100+1.6% | Added |
| Affinity Asset Advisors, LLC | 3,972,318 | $11.0M | 1.72% | +1,150,000+40.7% | Added |
| Sofinnova Investments, Inc. | 4,280,308 | $11.9M | 0.87% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $12.5M | 8.41% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 5,160,000 | $14.3M | 0.02% | −513,629−9.1% | Reduced |
| Samlyn Capital, LLC | 0 | $0 | 0.00% | −3,259,158−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −49,460−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −48,056−100.0% | Sold out |
| Alps Advisors Inc | 0 | $0 | 0.00% | −44,562−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −35,402−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −28,093−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −24,300−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −15,309−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −15,210−100.0% | Sold out |
| Values First Advisors, Inc. | 0 | $0 | 0.00% | −14,695−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −12,309−100.0% | Sold out |
| BFSG, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −475−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −179−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −66−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −44−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| GAMMA Investing LLC | 0 | $0 | 0.00% | −27−100.0% | Sold out |